EGFR and neoplasm: In addition to EGFR 19del, 1012-gene panel testing further demonstrated a TP53 missense mutation, RB1 truncating mutation, EGFR amplification, KIT amplification, and tumor mutational burden (TMB) of 11 mutations per megabase (mt/Mb) (Table 2).